How did Pfizer develop COVID-19 vaccine dose for young kids?
Updated: 9:15 PM EST Feb 3, 2022
ANNOUNCER: YOU’RE WATCHING WCVB NEWSCENTER 5T 5:30. ERIKA: COVID-19 VACCINES FOR CHILDREN YOUNGER THAN 5 COULD BE AVAILABLE AS EARLY AS NEXT MONTH. HERE TO ANSWERYOUR QUESTIONS IS DR. KRISTIN MOFFITT, AN INFECTIOUS DISEASE SPECIALISATT BOSTON CHILDREN’S HOSPITAL. ED: LET’S TALK FIRST ABOUT THIS ANNOUNCEMENT FROM PFIZER. AS YOU KNOW, THE COMPANY HAS ASKED THE FDA TO AUTHORIZETS I VACCINE FOR CHILDREN AGE 6 MONTHS TO 4-YEARS-OLD. ATWH CAN YOU TELL US ABOUT THE DOSING, AND ANY SAFETY CONCER?NS >> SURE. THE DOSING THAT WAS TRIALEDN I THE 6 MO THROUGH 4-YEAR-OLDS I THREE MICRO GRAM DOSE. THE 12 AND OVER DEOSS I 30 MICROGRAMS AND 5 TO 11-YEAR-OLD DOSESS I0 1 MICROGRAMS. IT’S LOWER. THAT DOSE WAS DETERMIDNE FROM A PHASE ONE DOSE FINDING STU.DY ONLY COUPLE OF DOZEN CHILDREN WERE GENIV DOSES. WE DON’T KNOW A TON ABOUT THE SAFE YET. EXCEPT THAT, IT SEEMS UNLIKELY THAT PFIRZE WOULD SUBMIT APPROVAL FORHE FDA. WE’LL KNOW LOT MORE ABOUT THE SAFETY WHICH INCLUDED A THOUSAND CHILDREN. ONCE THE DATA IS MADE PUBLIC. ERIKA: PFIZER WAS TOTALLY SATISFIED WHAT THEY WERE FINDING AND THEYER WE DOING A TWO-DEOS REGIMEN. PFIZER IS ALSO TESTING A 3-DOSE REGIMEN FOR KIDS IN THIS AGE GRP.OU SHOULDN’T THE FDA WAIT TO GET THOSE RESULTS BEFORE IT MAKES A DECISION ABOUT TWO DOSES? >> WHAT WE KNOW SO FAR IS WHAT PFIZER HAS TOLD US VIA PRESS RELEASES. THE IMNEMU RESPOESNS IN THOSE COUPLE THOUSAN 2D, T TO 3-YEAR-OLD, ETH UP MINE RESPONSES WERE NOT HIGH. THEY STARTED TO GIVE CHILDNRE IN THAT AGE RANGE A THIRD DOSE. WE KNOW THAT DATA FROM THE THIRD DOSE WILL BE FORTHCOMING IN MARCH. BECAUSE THERE ARE SO MANY INFECTIONS ONGOING NOW IN PEOPLE OF ALL AGES. PEOPLE WHO ARE NOT ELIGIBLE FOR VACCINATIONS IS UNDERSTANDABLE. IT’S REASONABLE TO HAVE THE FDA START TO REVIEW TWO-DOSE DATA. THE SAFETY STANDARDS WOULD NEED TO BE HIGH. IF THIS IS SAFE VACCINE AND OFFER SOME IMMUNITY, IST’ REASONABLE TO CONSIDER AUTHORIZING IT SO PARENT WHO WANT ITET G THEIR CHILDREN VACCINATED CAN SRTTA THE SERIES. ED: LET’S GET TO SOME OF THESE EMAILS FROM OUR VIEWERS. THE FIRST QUESTION IS FROM KAYLEIGH. IS ANYONE DEVELOPING A COVID VACCINE FOR CHILDREN THAT DOESN’T USE MRNA TECHNOLO?GY >> IT’S A GREAT QUESTION. THERE ARE LOT OF DIFFERENT TYPES OF VACCINES THAT ARE DEVELOPED AND TESTED. IT’S TREATED MOST OF THESE TESTS ARE GOING TO START IN OLDER INDIVIDUALS AND ADULTS. FOR EXAMPLE, IT’S VERY POSSIBLE THAT A PROTEIN-BASED VACCINE MAY BE TRIALED IN YOUNGER CHILDREN ONCE VERY SOLID EFFECTIVENESS AND SAFETY DEMONSTRATED IN ADULTS. THAT MIGHT INCLUDE A VACCINE SUCH AS THE NOVAVAX VACCINE WHICH YOU MAY HAVE HEARD HAS BEEN SUBMITTED TO THE FDA FOR REVIEWOR F AUTHORIZATION IN THOSE 18 AND OLDER. IT WAS AUTHORIZED FOR USE IN ADULTS OVER 18 IN THE U..K THAT’S A PR
Advertisement
How did Pfizer develop COVID-19 vaccine dose for young kids?
Updated: 9:15 PM EST Feb 3, 2022
Dr. Kristin Moffitt, an infectious disease specialist at Boston Children’s Hospital, explains the latest news about Pfizer’s request to authorize its COVID-19 vaccine for children.
Dr. Kristin Moffitt, an infectious disease specialist at Boston Children’s Hospital, explains the latest news about Pfizer’s request to authorize its COVID-19 vaccine for children.
Advertisement